Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with heterozygous familial hypercholesterolemia
For additional information please call: 1-800-718-1021
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| torcetrapib/atorvastatin | Drug | |||
| atorvastatin | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Change in intima media thickness as measures by carotid ultrasound |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in levels of lipids and other biomarkers. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Hartford | Connecticut | United States | |||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21613319 | Derived | Tajik P, Meijer R, Duivenvoorden R, Peters SA, Kastelein JJ, Visseren FJ, Crouse JR 3rd, Palmer MK, Raichlen JS, Grobbee DE, Bots ML. Asymmetrical distribution of atherosclerosis in the carotid artery: identical patterns across age, race, and gender. Eur J Prev Cardiol. 2012 Aug;19(4):687-97. doi: 10.1177/1741826711410821. Epub 2011 May 25. | |
| 20645885 |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Boston |
| Massachusetts |
| United States |
| Pfizer Investigational Site | Minneapolis | Minnesota | United States |
| Pfizer Investigational Site | New York | New York | United States |
| Pfizer Investigational Site | Houston | Texas | United States |
| Pfizer Investigational Site | Salt Lake City | Utah | United States |
| Pfizer Investigational Site | Seattle | Washington | United States |
| Pfizer Investigational Site | Vancouver | British Columbia | Canada |
| Pfizer Investigational Site | Winnipeg | Manitoba | Canada |
| Pfizer Investigational Site | Chicoutimi | Quebec | Canada |
| Pfizer Investigational Site | Montreal | Quebec | Canada |
| Pfizer Investigational Site | Québec | Quebec | Canada |
| Pfizer Investigational Site | Prague | Czechia |
| Pfizer Investigational Site | Kuopio | Finland |
| Pfizer Investigational Site | OYS | Finland |
| Pfizer Investigational Site | Paris | France |
| Pfizer Investigational Site | Toul | France |
| Pfizer Investigational Site | Brescia | Italy |
| Pfizer Investigational Site | Pavia | Italy |
| Pfizer Investigational Site | Alkmaar | Netherlands |
| Pfizer Investigational Site | Amsterdam | Netherlands |
| Pfizer Investigational Site | Delft | Netherlands |
| Pfizer Investigational Site | Goes | Netherlands |
| Pfizer Investigational Site | Groningen | Netherlands |
| Pfizer Investigational Site | Hoorn | Netherlands |
| Pfizer Investigational Site | Leiden | Netherlands |
| Pfizer Investigational Site | Nijmegen | Netherlands |
| Pfizer Investigational Site | Rotterdam | Netherlands |
| Pfizer Investigational Site | Sliedrecht | Netherlands |
| Pfizer Investigational Site | Utrecht | Netherlands |
| Pfizer Investigational Site | Waalwijk | Netherlands |
| Pfizer Investigational Site | Parow | Cape Town | South Africa |
| Pfizer Investigational Site | Parktown | Johannesburg | South Africa |
| Pfizer Investigational Site | Cape Town | South Africa |
| Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and Radiance 2 Study Groups. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med. 2010 Sep;42(6):447-64. doi: 10.3109/07853890.2010.499132. |
| 20228610 | Derived | Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and 2 Study Groups. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. J Atheroscler Thromb. 2010 May;17(5):526-35. doi: 10.5551/jat.3269. Epub 2010 Mar 13. |
| 19029469 | Derived | Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. |
| 17407645 | Derived | Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML; RADIANCE 1 and 2 Study Investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin. 2007 Apr;23(4):885-94. doi: 10.1185/030079907x182121. |
| 17387131 | Derived | Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007 Apr 19;356(16):1620-30. doi: 10.1056/NEJMoa071359. Epub 2007 Mar 26. |
| ID | Term |
|---|---|
| D006938 | Hyperlipoproteinemia Type II |
| D006949 | Hyperlipidemias |
| ID | Term |
|---|---|
| D008052 | Lipid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006951 | Hyperlipoproteinemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C483909 | torcetrapib |
| D000069059 | Atorvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided